| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Harvard Biosciences, Inc. |
| 84 October Hill Road, Holliston, MA 01746 * (508) 893-8066 |
| Business Description | The company is a leading global developer, manufacturer and marketer of innovative, enabling tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. |
| Offering Information Company has | |||
| Trading As | HBIO (NASNTL) | Industry | Manufacturing (SIC 3826) |
| Type of Stock Offered | Common Shares | Filing Date | 9/18/00 |
| Domestic Shares Offered | 6,422,450 | Offer Date | 12/6/00 |
| Foreign Shares Offered | 0 | Filing Range | $9.00 - $10.00 |
| Company Shares | 6,250,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 172,450 | Gross Spread | - - |
| Gross Proceeds | $51,379,600 | Selling | - - |
| Expenses | - - | Reallowance | - - |
| Post-IPO Shares | 24,782,422 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Thomas Weisel Partners LLC | Lead Manager | (415) 364-2500 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 |
| Revenues | 10.032 | 8.198 | 11.464 | 12.154 | 26.178 | 11.533 | 14.458 |
| Income from Oper. | 0.494 | 0.977 | 2.199 | 2.412 | 1.196 | 1.313 | 2.227 |
| Net Income | -0.125 | 0.536 | 1.107 | 0.071 | -29.420 | -6.836 | -66.586 |
| E.P.S | -0.240 | 0.840 | 1.270 | -0.180 | -10.400 | -24.280 | -210.660 |
| Revenue Growth (%) | -18.28 | 39.84 | 6.02 | 115.386 | 25.36 | ||
| Net Income Growth (%) | - | 106.53 | -93.59 | - | - | ||
| Oper. Profit Margin (%) | 4.92 | 11.92 | 19.18 | 19.85 | 4.57 | 15.40 | 11.38 |
| Net Profit Margin (%) | - | 6.54 | 9.66 | 0.58 | - | - | - |
| Cash Flow - Oper. | 2.93 | 0.65 | 1.18 | ||||
| Cash Flow - Inv. | -8.55 | -7.07 | -1.31 | ||||
| Cash Flow - Fin. | 6.99 | 7.30 | 0.02 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 20.63 | Current Assets | 11.43 | Current Ratio | 1.50 |
| Total Liab. | 113.37 | Current Liab. | 7.62 | Debt Ratio | 549.43% |
| Total Equity | -92.74 | Working Cap. | 3.81 | Debt to Equity Ratio | - |
| Cash | 2.15 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for payment of existing debt, redemption of series A redeemable preferred stock, potential acquisitions, working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Goodwin Procter & Hoar |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Ascent Venture Partners II, L.P. | 24.30 | |
| Ascent Venture Partners, L.P. | 15.70 | |
| First New England Capital, L.P. | 12.20 | |
| NEGF, II, L.P. | 5.90 | |
| Note: represents ownership of 5% or more prior to the offering. | ||